EUVIMEDEUVIMED entdecken
Crossref

B2R-D2R Interaction in Prolactinomas and Nonfunctional Adenomas: Impact on Dopamine Resistance

Alejandra Abeledo-Machado iD, Josep Argerich iD, Agustín Yaneff iD, Noemi Vidal iD, Claudia García-Roca, Dana Bornancini iD, Milagros Peña-Zanoni iD, Mariela M Gironacci iD, Carina Shayo iD, Francisco Ciruela iD, Graciela Díaz-Torga iD

Endocrinology · 2024

DOI: 10.1210/endocr/bqae144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, 2024. Verfasst von Alejandra Abeledo-Machado und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Fisiopatología Hormonal, IBYME-CONICET, C1428ADN Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Prolactinoma, Receptors, Dopamine D2, Pituitary Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Fondo para la Investigación Científica y Tecnológica, Ministerio de Ciencia, Innovación y Universidades, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolactinomas, the most common pituitary-secreting adenomas, can be effectively treated with dopamine D2 receptor (D2R) agonists. However, a subset of them (∼20%) are resistant to dopamine-based therapies and require extirpation. The molecular mechanisms underlying their escape from dopaminergic regulation are not fully elucidated and may include alterations in D2R signaling. D2R can heteromerize with other G protein-coupled receptors, resulting in modulation of dopaminergic signaling. Because the bradykinin receptor type 2 (B2R) is overexpressed in prolactinomas, we interrogated whether this dopaminergic dysregulation observed in some prolactinomas may depend on a physical and functional interaction between D2R and B2R. The formation of B2R-D2R complexes in cultured cells transiently expressing both receptors was validated using NanoBiT technology. Interestingly, although D2R stimulation did not alter B2R-induced intracellular calcium mobilization, B2R stimulation abolished D2R signaling through modulation of cAMP. The existence of B2R-D2R complexes in pituitary adenomas biopsies was evaluated using an ALPHALisa approach. Importantly, B2R-D2R complexes were detected in human prolactinomas and nonfunctioning pituitary adenomas, but not in mixed (prolactin + growth hormone)-secreting adenomas. These results suggest that overexpression of B2R in resistant prolactinomas may promote the formation of B2R-D2R complexes, with B2R precluding D2R signaling, thus generating resistance to D2R agonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProlactinomaReceptors, Dopamine D2Pituitary NeoplasmsHumansDrug Resistance, NeoplasmAdenomaDopamineFemaleDopamine AgonistsMaleAdultSignal TransductionAnimalsHEK293 CellsMiddle Aged

Stichwörter der Autor:innen

B2RD2Rheteromerspituitaryprolactinomasignaling

Substanzen

Receptors, Dopamine D2DopamineDopamine AgonistsDRD2 protein, human

Autor:innen und Institutionen

  • Laboratorio de Fisiopatología Hormonal, IBYME-CONICET, C1428ADN Buenos Aires, Argentina.
  • Department of Pathology and Experimental Therapeutics, Pharmacology Unit, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, 08907 Barcelona, Spain.
  • Neuropharmacology & Pain Group, Neuroscience Program, Bellvitge Institute for Biomedical Research, 08907 Barcelona, Spain.
  • Facultad de Farmacia y Bioquímica, Instituto de Investigaciones Farmacológicas (ININFA-UBA-CONICET), Universidad de Buenos Aires, C1113AAD Buenos Aires, Argentina.
  • Neurohatology, Servei d´Anatomia Patològica, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain.
  • Facultad de Farmacia y Bioquímica, Departamento de Química Biológica and IQUIFIB (UBA-CONICET), Universidad de Buenos Aires, C1113AAD Buenos Aires, Argentina.

ORCID-Profile: Alejandra Abeledo-Machado, Josep Argerich, Agustín Yaneff, Noemi Vidal, Dana Bornancini, Milagros Peña-Zanoni, Mariela M Gironacci, Carina Shayo, Francisco Ciruela, Graciela Díaz-Torga

Förderung

  • Fondo para la Investigación Científica y Tecnológica
  • Ministerio de Ciencia, Innovación y Universidades
  • European Regional Development Fund
  • Centres de Recerca de Catalunya
  • Boehringer Ingelheim Fonds

Zitieren

APA

Abeledo-Machado, A., Argerich, J., Yaneff, A., Vidal, N., García-Roca, C., Bornancini, D., Peña-Zanoni, M., Gironacci, M. M., Shayo, C., Ciruela, F., & Díaz-Torga, G. (2024). B2R-D2R Interaction in Prolactinomas and Nonfunctional Adenomas: Impact on Dopamine Resistance. Endocrinology. https://doi.org/10.1210/endocr/bqae144

Vancouver

Abeledo-Machado A, Argerich J, Yaneff A, Vidal N, García-Roca C, Bornancini D, et al. B2R-D2R Interaction in Prolactinomas and Nonfunctional Adenomas: Impact on Dopamine Resistance. Endocrinology. 2024. doi:10.1210/endocr/bqae144

BibTeX
@article{AbeledoMachado2024,
  author = {Abeledo-Machado, Alejandra and Argerich, Josep and Yaneff, Agustín and Vidal, Noemi and García-Roca, Claudia and Bornancini, Dana and Peña-Zanoni, Milagros and Gironacci, Mariela M and Shayo, Carina and Ciruela, Francisco and Díaz-Torga, Graciela},
  title = {B2R-D2R Interaction in Prolactinomas and Nonfunctional Adenomas: Impact on Dopamine Resistance},
  journal = {Endocrinology},
  year = {2024},
  doi = {10.1210/endocr/bqae144}
}
Kostenlos starten →